| Project/Area Number |
26670119
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
Matsumoto Akio 千葉大学, 医学(系)研究科(研究院), 准教授 (60437308)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 分子状水素 / β受容体 / グレリン / 転写制御 / 受容体 |
|---|
| Outline of Final Research Achievements |
The therapeutic potential of molecular hydrogen is emerging in a number of human diseases and in their animal models. However, the molecular mechanism in these hydrogen effects has not been elucidated enough. We showed that H2 supplementation increases gastric expression of mRNA encoding ghrelin and ghrelin secretion, which are antagonized by the β1-adrenoceptor blocker. Thus, we focused on β-adrenoceptor signaling to investigate the molecular mechanism of action induced by hydrogen. Ghrelin gene promotor activity assay, real-time analysis of intracellular cAMP measurements, and in vivo analysis with mouse provided evidence that molecular hydrogen enhances β-adrenoceptor signal.
|
